Ketamine Clinics Los Angeles

What Ketamine Clinics Los Angeles does

Ketamine Clinics Los Angeles (KCLA) is a family-founded, private mental health clinic established in 2014 by Dr. Steven L. Mandel, MD (President & Founder) and Sam Mandel (COO). The clinic operates from a single location at 6801 Park Terrace, Suite 525 in Los Angeles and specializes in interventional psychiatry for adults with mood disorders, trauma, addiction, and chronic pain that have not responded to conventional treatment. Core services are IV Ketamine Infusion Therapy (delivering 100% bioavailability via precisely controlled intravenous dosing), Transcranial Magnetic Stimulation (TMS), FDA-approved Spravato (esketamine nasal spray), and Holistic Psychiatry with medication management. KCLA reports 35,000+ treatments administered to 6,000+ patients since founding, with an 83% self-reported success rate for IV ketamine and 70–80% for TMS.

The business model is a hybrid professional services and fee-for-treatment model. TMS and Holistic Psychiatry are covered by most major insurance plans (Aetna, Anthem Blue Cross, Blue Shield of California, Cigna, Kaiser Permanente, Medicare, Optum, Tricare), while ketamine infusion therapy is largely self-pay with optional interest-free financing for up to 24 months. Patient acquisition is direct-to-consumer: free phone consultations, virtual treatment evaluations, website booking, and multi-channel content marketing across Facebook, Instagram, LinkedIn, X, YouTube, and TikTok, supplemented by extensive earned media coverage (BuzzFeed, ABC, CBS, Fox, MSNBC, GQ, Wired, Hollywood Reporter) and celebrity testimonials.

Operationally, KCLA runs as a single-site clinic with a small named team (Dr. Mandel, COO, Director of Operations, one physician assistant, two nurses, patient care coordinator, administrative assistant), no disclosed external funding or parent company, and no subsidiaries. The clinic has progressively expanded its treatment menu from ketamine-only in 2014 to include TMS and Spravato in 2017, plus addiction and chronic pain specialties, indicating a deliberate strategy to position itself as a multi-modality interventional psychiatry platform within the Los Angeles market.

Name

Ketamine Clinics Los Angeles

Legal name

Ketamine Clinics Los Angeles

Website

https://ketamineclinics.com

Company type

Private

Founded year

2014

Operating status

Operating

Headcount range

1–10 employees

Short description

Ketamine Clinics Los Angeles (KCLA) is a family-founded, single-site Los Angeles clinic providing IV ketamine infusion therapy, TMS, Spravato, and holistic psychiatry to adults with treatment-resistant depression, anxiety, PTSD, OCD, addiction, and chronic pain conditions since 2014.

Ownership category

akta.pro rank

Product category

Mental Health Services

NAICS

Outpatient Mental Health and Substance Abuse Centers (621420), Offices of Physicians, Mental Health Specialists (621112)

SIC

Services-Specialty Outpatient Facilities, Nec (8093), Services-Offices & Clinics Of Doctors Of Medicine (8011)

akta.pro primary industry

Outpatient Mental Health & Counseling Clinics (HLAFABAC)

akta.pro secondary industries

Outpatient Mental Health Clinics & Counseling Centers (HLAFACAA), Psychiatry & Medication Management Platforms (HLALAEAB)

Keywords

• Ketamine infusion therapy
• Transcranial magnetic stimulation
• Treatment resistant depression
• Mental health clinic
• Psychiatric medication management

Headquarters

HQ city

Los Angeles

HQ country

United States

HQ region

North America

Offices1 record

Markets served

GTM type

B2C

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Technology or R&D, Infrastructure

Revenue model

1. Ketamine Infusion Therapy: IV ketamine infusion treatments for mental health conditions. Covered by some insurance plans, with out-of-pocket options for self-pay patients who can also access interest-free financing.
2. TMS Therapy: Transcranial Magnetic Stimulation treatments. Covered by most insurance plans.
3. Holistic Psychiatry: Psychiatric medication management with easy virtual and in-person visits. Covered by most insurance.
4. Spravato Treatment: Esketamine nasal spray treatment (FDA-approved for treatment-resistant depression).

Pricing tiers

Go-to-market motion1 record

Distribution channels2 records

Marketing channels9 records

Core offering

Ketamine Clinics Los Angeles operates an outpatient mental health clinic delivering IV ketamine infusion therapy for treatment-resistant depression, anxiety, PTSD, OCD, addiction, and chronic pain, complemented by TMS (Transcranial Magnetic Stimulation), Spravato (esketamine nasal spray), and holistic psychiatric medication management. Treatments are administered at a single Los Angeles facility with free phone consultations, virtual evaluations, insurance billing for TMS/psychiatry, and self-pay financing for ketamine.

Product overview

Ketamine Clinics Los Angeles (KCLA) is a family-founded mental health clinic pioneering innovative psychiatry since 2014. The company operates a unified treatment platform offering four core services: Ketamine Infusion Therapy (IV administration with 83% success rate), TMS Therapy (non-invasive FDA-approved with 70-80% success rate), Spravato Treatment (esketamine nasal spray), and Holistic Psychiatry. These services are complemented by addiction treatment and depression assessment tools. The clinic provides in-person treatment at their Los Angeles facility with some virtual care options for psychiatric services.

Differentiator

Problem solved

Functional benefit

Products and services

• Ketamine Infusion Therapy IV ketamine infusion therapy delivered directly into the bloodstream for 100% bioavailability, used to treat treatment-resistant depression, anxiety, PTSD, OCD, and other mood disorders in adult patients. Reported 83% success rate.
• TMS Therapy (Transcranial Magnetic Stimulation) Non-invasive, FDA-approved brain stimulation treatment using magnetic fields to stimulate nerve cells, used to treat depression and other conditions in adult patients. Covered by most insurance plans with a reported 70-80% success rate.
• Spravato Treatment FDA-approved esketamine (S-ketamine) nasal spray treatment offered as an alternative to IV ketamine therapy for adult patients with treatment-resistant depression.
• Holistic Psychiatry

Quantifiable outcome

• 83% success rate for IV ketamine treatments
• +2 more outcomes

Named customers5 records

Segments4 records

Ideal customer profiles4 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Feature1 record

Scale indicators5 records

Recent moves6 records

Expansion highlights6 records

Direct peers

• Mindbloom: A leading at-home ketamine therapy provider serving treatment-resistant depression and anxiety patients across multiple U.S. states; directly comparable in target patient (treatment-resistant mental health) and core service (clinician-supervised ketamine dosing), though via a different delivery model.
• Greenbrook TMS: Largest U.S. provider of Transcranial Magnetic Stimulation (TMS) therapy, a core service in KCLA's multi-modality platform; highly comparable as a multi-site outpatient psychiatry operator in treatment-resistant depression.
• Novamind (TPCO Holding Corp.): Operated outpatient mental health clinics offering ketamine therapy and psychedelic medicine alongside traditional psychiatry; directly comparable as a multi-site ketamine and mental health clinic operator, now part of TPCO.
• Field Trip Health (now at-home: Field Trip at Home): One of the earliest multi-site ketamine therapy operators; offered IV/injection ketamine for depression, anxiety, and PTSD in clinics across the U.S. and Canada before restructuring to focus on at-home ketamine, and is a direct comparable in clinical model and patient segment.
• Ketamine Wellness Centers (KWC): Multi-state operator of outpatient ketamine infusion clinics for depression, PTSD, and chronic pain; a direct comparable in clinical model, indication set, and clinic-based delivery.

Broad incumbents

• Compass Pathways: Public company developing psilocybin therapy for treatment-resistant depression; an adjacent/emerging peer in psychedelic-assisted mental health care targeting the same patient population as KCLA's ketamine practice.
• NeuroStar (Neuronetics): Manufacturer and operator behind one of the most widely used TMS systems and a network of treatment centers; comparable as a TMS delivery and treatment-network peer, though also a potential equipment/infrastructure counterparty to KCLA.
• Cedars-Sinai / UCLA Behavioral Health: Major Los Angeles academic medical systems offering psychiatric and TMS services, including treatment-resistant depression programs; a regional incumbent peer competing for the same patient base and payer relationships in KCLA's home market.

Emerging players

• Innerwell: Telehealth-forward ketamine-assisted psychotherapy provider for depression, anxiety, and PTSD; comparable in target conditions and ketamine modality but differentiated by virtual-first delivery and a younger scale.
• Wondermed: Specialty ketamine clinic operator focused on treatment-resistant mood disorders; comparable in service line and patient segment, with a smaller and more regional footprint than KCLA.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• Xx.com/ketamineclinics
• YouTubeyoutube.com/c/KetamineClinicsofLosAngeles
• Facebookfacebook.com/KetamineClinicsLA
• LinkedInlinkedin.com/company/ketamineclinicsla
• Instagraminstagram.com/KetamineClinicsLA
• TikToktiktok.com/@ketamineclinicsla/video/7112225500726136106

Revenue estimate

Valuation estimate

Number of profiles

Profiles3 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Ketamine Clinics Los Angeles